Liver Disease Clinical Trials in New York

Showing 61-80 of 103 trials

Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant

NCT02533934

Retrospective/Prospective, open-label study using sofosbuvir based DAA therapy to treat HIV/HCV coinfected pre or post liver transplant participants

HIVHepatitis CCirrhosis

University of California, San Francisco68 participantsStarted Aug 2016

San Francisco, California, United States • Washington D.C., District of Columbia, United States • Baltimore, Maryland, United States +5 more locations

COMPLETEDPhase 2< 1 mile

A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH

NCT02784444

This is a randomized, double-blinded study of three doses of MSDC-0602K or placebo given orally once daily to subjects with biopsy proven NASH with fibrosis and no cirrhosis.

Non-alcoholic Fatty Liver DiseaseNon-alcoholic SteatohepatitisNASH - Nonalcoholic Steatohepatitis

Cirius Therapeutics, Inc.392 participantsStarted Sep 2016

Chandler, Arizona, United States • Tucson, Arizona, United States • Chula Vista, California, United States +40 more locations

Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant

A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH

Liver Disease Trials in Other Cities

LAGB as a Treatment for Morbid Obesity in Adolescents

The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy

Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis

Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis

Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis

An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis

Evaluating Alcohol Use in Alcoholic Liver Disease

Assessing Cirrhosis Quality of Care While Accounting for Cost

Using Addiction Comprehensive Health Enhancement Support System (ACHESS) in an Alcoholic Liver Disease Population

Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study

Remote Ischemic Conditioning in Abdominal Surgery

Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH

Effects of Probiotic on Inflammation and Microbiota in Patients With NASH

Non-invasive Methods and Surgical Risk Stratification in Cirrhotics Undergoing Elective Extrahepatic Surgery

The Patient-Reported Outcomes Project of HCV-TARGET

Tesamorelin Effects on Liver Fat and Histology in HIV

Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function

Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)

Other Conditions in New York